XML 45 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Shareholders' Equity, Stock Plans and Preferred Stock (Tables)
12 Months Ended
Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The table below shows the weighted average assumptions the Company used to develop the fair value estimates under its option valuation model:
 
Year Ended December 31,
 
2014
 
2013
 
2012
Expected volatility (range)
N/A(1)
 
N/A(1)
 
58% - 59%
Risk free interest rate (range)
N/A(1)
 
N/A(1)
 
0.80% - 1.03%
Expected dividends
N/A(1)
 
N/A(1)
 
3.75%
Weighted average expected term (years)
N/A(1)
 
N/A(1)
 
6

___________
(1)
The Company did not issue any options or other equity grants that would require application of the Black-Scholes-Merton equity grant valuation model during the years ended December 31, 2014 and 2013. All equity grants during these periods were restricted common shares which are valued using an intrinsic valuation method based on market price.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
The table below describes the resulting weighted average grant date fair values calculated as well as the intrinsic value of options exercised under the Company's equity awards during each of the following years:
 
 
Year Ended
December 31,
 
 
    2014(1)
 
2013(1)
 
2012
Weighted average grant date fair value
 

 
$

 
$
2.29

Total intrinsic value of exercises
 
$
126,000

 
$
53,000

 
$
12,000


___________
(1)
The Company did not issue any options or other equity grants that would require application of the Black-Scholes-Merton equity grant valuation model during the years ended December 31, 2014 and 2013. All equity grants during these periods were restricted common shares which are valued using an intrinsic valuation method based on market price.
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range
The following table summarizes information regarding stock options and SOSAR grants outstanding as of December 31, 2014:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.40 to $11.59
 
$
11.14

 
57,000

 
$

 
57,000

 
$

$2.37 to $6.21
 
$
5.50

 
214,000

 
849,000

 
201,000

 
801,000

 
 
 
 
271,000

 
 
 
258,000

 
 
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
SOSARs/
 
Average
 
Options
 
Exercise Price
Outstanding, December 31, 2013
333,000

 
$
6.64

Granted

 

Exercised
(25,000
)
 
4.58

Expired or cancelled
(37,000
)
 
7.87

Outstanding, December 31, 2014
271,000

 
$
6.67

 
 
 
 
Exercisable, December 31, 2014
258,000

 
$
6.71

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2013
118,000

 
$
5.41

Granted
68,000

 
5.51

Dividend Equivalents
4,000

 
8.06

Vested
(57,000
)
 
5.61

Cancelled
(3,000
)
 
5.50

Outstanding December 31, 2014
130,000

 
$
5.45



Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2013
41,000

 
$
5.35

Granted
25,000

 
5.51

Dividend Equivalents
1,000

 
8.15

Vested
(21,000
)
 
5.69

Cancelled

 

Outstanding December 31, 2014
46,000

 
$
5.35

Schedule of Auction Market Preferred Securities by Stock Series
The following table reflects activity in the Series C Preferred Stock:
Series C Preferred Stock
 
 
2014
 
2013
 
2012
Balance at the beginning of the period
 
$
4,918,000

 
$
4,918,000

 
$
4,918,000

Redemption of preferred stock
 
(4,918,000
)
 

 

Balance at the end of the period
 
$

 
$
4,918,000

 
$
4,918,000